



Quanta to Present at the 39th Annual Dialysis Conference

Alcester, Warwickshire, UK, 6 March 2019: Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a pioneering British medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announces that the Company will be presenting at the 39th Annual Dialysis Conference (ADC), which runs from 16 to 19 March 2019, at the Sheraton Dallas Hotel, Texas, USA.

Dr. Paul Komenda, Chief Medical Officer, will provide an update on SC+, explaining how it enables choice, efficiency and empowerment to both patients and physicians in the “Home Dialysis Machines” session on Monday, 18 March at 3:00pm. The presentation will be followed by a device demonstration at 3:45pm.

Full details of the session are as follows:

Session: Home Dialysis Machines
Date: Monday 18 March
Time: 3:00pm
Location: 04H

If you would like to arrange a meeting with John E. Milad, Chief Executive Officer or Paul Komenda, Chief Medical Officer, at the conference, please contact enquiries@quantadt.com.

-ENDS-

For more information about Quanta, please contact:

Quanta

John E. Milad,
Chief Executive Officer

T: +44 (0)1789 400043
E: enquiries@quantadt.com

Consilium Strategic Communications

Mary-Jane Elliott / Matthew Neal / Lindsey Neville

T: +44 (0)203 709 5708
E: quanta@consilium-comms.com

About SC+

SC+ is a small, simple and powerful haemodialysis system designed to provide greater flexibility around where, when and how patients manage and receive their dialysis therapy. As a CE marked medical device, SC+ has been successfully piloted with the NHS, demonstrating clinical efficacy and performance compatible with traditional treatment regimens used in-centre. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The small form factor and simple-to-use design are intended to enable a broader range of users—including patients themselves—to manage dialysis therapy delivery across a wide range of settings—from the clinic to the home.

About Quanta

Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use both in the clinic and the home. Quanta's lead product SC+ is designed to empower dialysis patients by giving them greater flexibility, convenience and control over the delivery of their life-sustaining renal replacement therapy. Quanta is based in Alcester, UK, and was founded in 2008 as a spin out from IMI plc. The company has attracted funding from a group of leading investors, including: Wellington Partners, Seroba Life Sciences, b-to-v Partners, Stage Capital, ALIAD, CITA, Seventure Partners and Kuwait Life Sciences Company.

For more information, please visit: www.quantadt.com.

SC+ is not yet FDA cleared and not yet available for sale in the USA.